Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF
about
TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivoPotent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization.Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide.The TLR4 D299G and T399I SNPs are constitutively active to up-regulate expression of Trif-dependent genes.The WSX-1 pathway restrains intestinal T-cell immunityTRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft toleranceDifferential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturationA unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.Use of defined TLR ligands as adjuvants within human vaccines.The TLR4-TRIF pathway can protect against the development of experimental allergic asthma.De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways.Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis.
P2860
Q27332276-FE33B565-AD48-47B0-8061-45C4CE6FA0A0Q33942532-BCA95F1A-71E8-4D1A-8C83-818B5255ACA3Q34258820-B530227E-C530-42B0-BFE0-32A945EA4C7CQ34445270-C4C58956-F14F-4F02-8BD4-2EAEDA0E0F42Q34538706-A85B831E-FA49-469B-AC1A-CDB8D9E990C9Q34607160-7B4331C0-8835-45A3-8EC4-9C2B02A5DBB7Q35088222-E70EF4D7-C3C1-466F-B3AA-E7181B5CC945Q35893430-06C5F658-EE6C-4645-B103-C3183158D4ECQ36300342-109DE895-2DB6-4F70-A37E-6A47FC87CBC4Q36511199-8032E5DA-5A3C-45EA-902D-3BD070B14A54Q37714634-028973FB-56D8-4778-A06F-8430BADC429BQ37825528-0A798629-49F4-4066-859F-EEAED0E19020Q38787350-57B2F859-74E1-4C12-B53A-91FABDBD4769Q40099747-512FF770-2253-4079-9B02-AC4AC0868FF0Q51041005-89EC38D6-18CF-40BD-A710-F411020A2429Q51830691-77DA5C7F-8491-426F-86F9-41C0638083D1
P2860
Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@ast
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@en
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@nl
type
label
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@ast
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@en
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@nl
prefLabel
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@ast
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@en
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@nl
P2093
P2860
P356
P1476
Lipopolysaccharide potentiates ...... nlymphoid tissues through TRIF
@en
P2093
Anthony T Vella
Jeremy P McAleer
Robert J Rossi
P2860
P304
P356
10.4049/JIMMUNOL.0803616
P407
P577
2009-05-01T00:00:00Z